LIVZON PHARMA (01513) announced that as of October 31, 2025, the company had repurchased a total of 15.38 million A shares via centralized bidding, accounting for 1.70% of its total share capital. The highest purchase price was RMB 41.99 per share, while the lowest stood at RMB 33.21 per share. The total capital used amounted to RMB 570 million (excluding transaction fees). The repurchase was executed in accordance with the company's predetermined share buyback plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.